Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical firm dedicated to discovering, developing, and providing therapies for patients suffering from sickle cell disease (SCD) who currently lack adequate treatment options. Its marketed product, Oxbryta tablets, offers a once-daily, oral treatment for SCD. Furthermore, GBT is conducting a Phase IIa clinical trial to assess the safety and pharmacokinetic profile of single and multiple doses of Oxbryta in younger SCD patients, including adolescents and children. In its development pipeline, inclacumab stands as a primary candidate – a novel human monoclonal antibody currently undergoing Phase IIIa clinical trials. This investigational drug aims to diminish the occurrence of painful vaso-occlusive crises and subsequent hospitalizations. Also in early-stage development (Phase I) is GBT601, a compound designed to inhibit hemoglobin polymerization. The company holds a licensing and collaborative agreement with Syros Pharmaceuticals, Inc. focused on identifying, advancing, and commercializing treatments for both SCD and beta thalassemia. Additionally, GBT collaborates with Sanofi S.A. on two separate early-stage research initiatives targeting SCD. Established in 2011, Global Blood Therapeutics, Inc. maintains its headquarters in South San Francisco, California.